Copanlisib Plus Rituximab-Based Immunochemotherapy for Relapsed Indolent B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CHRONOS-4: Phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma
Blood Adv 2024 Jul 26;[EPub Ahead of Print], PLL Zinzani, H Wang, J Feng, TM Kim, R Tao, H Zhang, LM Fogliatto, C Maluquer Artigal, M Özcan, EP Yanez Ruiz, WS Kim, D Kirtbaya, I Kriachok, F Maciel, H Xue, K Bouabdallah, C Phelps, S Chaturvedi, A Weispfenning, PN Morcos, FCA Odongo, V Buvaylo, BH Childs, M Dreyling, MJ Matasar, P GhioneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.